Table 3.
List of drugs withdrawn from the market
| Name of drug | Year of withdrawal | Cause for withdrawal |
|---|---|---|
| Troglitazone | 2000 | Hepatotoxicity |
| bromfenac | 1998 | Hepatotoxicity |
| Trovafloxacin | 1999 | Hepatotoxicity |
| Ebrotidine | 1998 | Hepatotoxicity |
| Nimesulide | 1999 | Hepatotoxicity |
| Nefazodone | 2003 | Hepatotoxicity |
| Ximelagatran | 2006 | Hepatotoxicity |
| Pemoline | 2010 | Hepatotoxicity |
| Tegaserod maleate | 2007 | Cardiotoxicity |
| Rofecoxib | 2004 | Cardiotoxicity |
| Grepafloxacin | 1999 | Cardiac repolarization; QT interval prolongation; ventricular arrhythmia (torsade de pointes) |
| Efalizumab | 2009 | Progressive multifocal leukoencephalopathy |
| Cisapride | 2000 | Serious cardiac arrhythmias |
| Pergolide | 2007 | Valve regurgitation |
| Gemtuzumab ozogamicin | 2010 | Increased risk of death and veno-occlusive disease |
| Sibutramine | 2010 | Increased cardiovascular and stroke risk |
| Astemizole | 1999 | Torsade de Pointes (LQTS; prolonged QT intervals) |
| Propoxyphene | 2010 | Serious cardiotoxicity |
| Valdecoxib | 2005 | Serious cardiovascular adverse events gastrointestinal bleeding |
| Cerivastatin | 2001 | Rhabdomyolysis which led to kidney failure; |
| Isotretinoin | 2009 | Increased risk of birth defects, miscarriages, and premature births; suicidal tendencies |
| Alatrofloxacin | 2000 | Hepatotoxicity |
LQTS - Long QT syndrome